Search the Newsreel

Entera Bio shares slip as Q2 loss comes in wider than expected

Medical research testing ©rawpixel Entera Bio Ltd. (NASDAQ:ENTX) shares fell 1.05% in pre-market trading after the clinical-stage biotechnology company reported a larger-than-expected second-quarter loss as spending increased ahead of a pivotal trial for its oral osteoporosis treatment EB613. The company posted a loss of …

Entera Q2 Loss Widens, FDA Backs EB613 For Phase 3 Osteoporosis Trial, Expects Data In Q2 Of FY28

(RTTNews) - Entera Bio Ltd. (ENTX), a clinical-stage biopharmaceutical company, reported a wider net loss for the second quarter, on surge in financial expense and more than double the growth in research and development expenses. Further, the company plans to initiate Phase 3 study …

Entera Bio Ltd. Q2 2026: Revenue $0M, Net loss $7.31M, EPS ($0.14) — 10-Q Summary

Entera Bio Ltd. (ENTX) reported its Q2 2026 financial results, showing no revenue and a net loss of $7.31 million, or $0.14 per share, which is a wider loss compared to the previous year. Despite the financial losses, the company highlighted significant pipeline progress …

Entera Bio (NASDAQ:ENTX) Announces Earnings Results

Entera Bio (NASDAQ:ENTX) reported a quarterly loss of $0.14 per share, missing analyst expectations of a $0.08 loss. Despite this, ENTX shares rose slightly to $2.87. The company, a clinical-stage biopharmaceutical firm focusing on orally delivered peptide therapeutics, has a market capitalization of $141.5 …

Entera Bio (ENTX) awards 180,000 options to Chief of R&D

Entera Bio Ltd. has granted its Chief of R&D, Gregory Burshtein, 180,000 stock options to purchase ordinary shares at an exercise price of $1.37 per share. These options, which expire on May 7, 2036, will vest over a three-year period starting May 7, 2026, …

Entera Announces Second Quarter 2026 Financial Results and Business Updates

U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis Oversubscribed $275 Million Private Placement Led by BVF Partners L.P. (“BVF”) with Participation …

Entera Bio Ltd (ENTX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Entera Bio (ENTX): Longitude entities report 4.6% ownership, Seven Fleet 4.1%

A Schedule 13G filing for Entera Bio Ltd. (ENTX) reveals that Longitude Venture Partners V, L.P. (LVPV) and related entities report a 4.6% ownership stake, comprising 7,843,138 ordinary shares. The filing also indicates that Seven Fleet may beneficially own 4.1% of the ordinary shares, …

Entera Bio (ENTX) sees BVF build 9.99% stake after $275M financing

Biotechnology Value Fund (BVF) and its affiliates have reported a 9.99% beneficial ownership stake in Entera Bio Ltd. (ENTX) following significant financing rounds in April and July 2026. These financings, including a $275 million private placement in July, led to BVF acquiring over 17 …

BVF Partners Wins Board Designation Rights at Entera Bio with 9.99% Stake

BVF Partners L.P. has disclosed a 9.99% stake in Entera Bio Ltd.'s ordinary shares, securing the right to designate two directors to Entera Bio's board following two private placements. This move signifies a hands-on approach to governance, with provisions for board representation to scale …

Seven Fleet funds disclose 4.1% Entera Bio (ENTX) stake and shared voting power

Seven Fleet funds, including Seven Fleet Horizon Master Fund and Seven Fleet Master Fund, along with Brian Liu, have disclosed a collective 4.1% beneficial ownership in Entera Bio (ENTX), amounting to 7,053,898 Ordinary Shares. This stake is reported with shared voting and dispositive power. …

Entera Bio (ENTX) stake of 12.25M shares reported by TCG Crossover

TCG Crossover Fund III, L.P., TCG Crossover GP III, LLC, and Chen Yu have reported a beneficial ownership of 12,254,901 ordinary shares of Entera Bio Ltd. (ENTX), which constitutes a 7.1% stake in the company. This ownership is based on 172,251,449 ordinary shares outstanding, …

Vivo Opportunity group (NASDAQ: ENTX) discloses 12.3M-share holding in Entera Bio

Vivo Opportunity group has disclosed a significant stake in Entera Bio (NASDAQ: ENTX) through a Schedule 13G filing. Vivo Opportunity, LLC beneficially owns 11,817,401 Ordinary Shares, representing 6.9% of Entera Bio’s outstanding shares, while Vivo Opportunity Cayman, LLC holds an additional 437,500 shares, or …

Entera Bio’s EB613 data selected for plenary poster at ASBMR

Entera Bio Ltd. announced that post-hoc data from its Phase 2 clinical trial of EB613, an oral PTH(1-34) tablet for osteoporosis, has been selected for two presentations at the American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting. One of these presentations …

Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

Entera Bio Ltd. announced that its CEO, Miranda Toledano, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The company, a leader in oral peptide development, will also hold 1x1 meetings during the conference, which …

Entera Bio CEO to speak at Canaccord Genuity Growth Conference on Aug 12, 2026

Entera Bio Ltd., a clinical-stage company specializing in oral peptide therapies, announced that CEO Miranda Toledano will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. This event, held in Boston and streamed online, will provide …

Entera Bio CEO's Aug. 12 Fireside Chat Will Stream Online

Entera Bio (NASDAQ: ENTX) announced that CEO Miranda Toledano will participate in a fireside chat and 1x1 meetings at the Canaccord Genuity 46th Annual Growth Conference. The fireside chat is scheduled for August 12, 2026, at 1:00 p.m. Eastern Time in Boston, and a …

Entera Bio Ltd (ENTX) Institutional Confidence

Entera Bio Ltd (ENTX) has an institutional shareholding score of 3.00, placing it 192nd out of 384 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 17.10%, a 24.51% decrease quarter-over-quarter. James Simons is the largest institutional shareholder, holding 1.02% of …

Entera Bio Ltd (ENTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Entera Bio Ltd (ENTX), detailing its current price momentum score, support and resistance levels, and the status of common technical indicators and moving averages. The stock is currently trading between a resistance level of $4.24 and a …

Why the World's Leading Healthcare Funds All Wanted a Piece of Entera Bio (NASDAQ: ENTX)

Entera Bio (NASDAQ: ENTX) recently announced an oversubscribed $275 million private placement, attracting investments from leading healthcare funds like BVF Partners, Longitude Capital, and Vivo Capital. This significant capital raise for a company with a market capitalization under $60 million at the start of …

ENTX|Entera Bio Ltd|Price:2.975|Chg%:-0.285

This article provides a comprehensive stock analysis of Entera Bio Ltd (ENTX), highlighting its relatively healthy fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. It notes strong institutional ownership, a "Buy" rating from analysts with a high price …

Entera Bio Ltd. (ENTX) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live stock quotes and charts for Entera Bio Ltd. (ENTX) on NASDAQ, showing a current price of $3.15, up 5.00%. It also notes that there are currently no analyst ratings or earnings information available for the company. The site prominently features …

Greenberg Traurig Advises Entera Bio on Record $275M PIPE Financing

Greenberg Traurig successfully advised Entera Bio Ltd. on an oversubscribed $275 million PIPE financing, marking the largest publicly disclosed Israeli biotech PIPE financing on record. This substantial investment is expected to fund Entera Bio's operations through 2030 and support crucial Phase 3 studies for …

Entera Bio Rebounds As Investors Balance Phase 3 Funding Against Dilution Risk

Entera Bio shares rebounded despite broader market headwinds, following an oversubscribed private placement valued at $275 million. This financing is expected to extend the company's cash runway into 2030 and fund its Phase 3 program for EB613, an osteoporosis treatment. While the large capital …

Entera Bio Raises $275 Million in Market-Priced Private Placement Led by BVF

Entera Bio successfully completed a market-priced private placement, raising approximately $275 million at $2.04 per share through the issuance of ordinary shares and pre-funded warrants. The offering, led by BVF Partners, closed on July 28, 2026, and the proceeds are designated to fund a …

Entera Bio Shares Climb on $275M Private Placement

Entera Bio (NASDAQ: ENTX) shares rose significantly on Tuesday after the company announced a $275 million private placement with existing and new institutional investors. The funding is intended to advance its pipeline, including the EB613 program for hypoparathyroidism. The private placement is expected to …

Entera Bio Ltd. announced that it expects to receive $274.999977 million in funding from a group of investors

Entera Bio Ltd. has secured approximately $275 million in funding through an oversubscribed private placement. The financing involved issuing ordinary shares and pre-funded warrants to a group of investors, with BVF Partners L.P. leading the placement and participation from several new investors including Longitude …

Entera Bio raises $275m for Phase III osteoporosis drug trial

Entera Bio (Nasdaq: ENTX), an Israeli drug development company, announced a $275 million private placement, significantly boosting its market capitalization. This funding will support the company until 2030, including a crucial Phase III trial for its lead product targeting osteoporosis, aiming for FDA approval. …

Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement

Entera Bio Ltd. has announced an oversubscribed private placement expected to raise approximately $275 million. This funding, led by existing investor BVF Partners L.P. and including new investors, will extend the company's cash runway into 2030 and fully support Phase 3 registrational studies for …

ENTX Stock Explodes Higher As Traders Pounce On Breakout

Entera Bio Ltd. (ENTX) stock surged by 86.83% due to high trading sentiment around its pipeline developments. The company's stock experienced a significant breakout from its consolidation range, driven by its low float, solid cash reserves, and minimal debt despite having tiny revenue and …

Entera Bio Ltd (ENTX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on Entera Bio Ltd (ENTX)'s dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years, showing "No Data" for dividend dates. The article also presents current stock performance data, including …

Entera Bio Ltd (ENTX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Entera Bio Ltd (ENTX), listing both major institutional and individual shareholders, along with their respective proportions. It also includes a historical overview of institutional shareholdings and recent shareholder activity, such as changes in holdings by key investors. …

ENTX|Entera Bio Ltd|Price:2.050|Chg%:-0.080

Entera Bio Ltd (ENTX) is a clinical-stage biopharmaceutical company focusing on oral delivery of large molecule therapeutics, with candidates EB613 for osteoporosis and EB612 for hypoparathyroidism. The company's stock is currently priced at $2.05, down 3.76%, and multiple analysts rate it as a 'Buy' …